Companion Diagnostic Tests - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB509248174

Publication Date:

September 18, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global market for Companion Diagnostic Tests was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Companion Diagnostic Tests, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Companion Diagnostic Tests by region & country, by Type, and by Application.
The Companion Diagnostic Tests market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Companion Diagnostic Tests.
麻豆原创 Segmentation
By Company
F. Hoffman LA Roche Ltd.
QIAGEN, Illumina, Inc.
Abbott
Agilent Technologies, Inc.
Genomic Health, Inc.
BioMerieux SA, BioGenex
AGENDIA NV
Siemens Healthcare GmBH
Thermo Fisher Scientific, Inc.
Segment by Type:
Protein Detection
DNA Detection
Hybridization
Biomarker
Others
Segment by Application
Pharmaceutical and Biotechnology Companies
Medical Device Companies
Research Institutes
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Companion Diagnostic Tests manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Companion Diagnostic Tests in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Companion Diagnostic Tests in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Companion Diagnostic Tests Product Introduction
1.2 Global Companion Diagnostic Tests 麻豆原创 Size Forecast
1.3 Companion Diagnostic Tests 麻豆原创 Trends & Drivers
1.3.1 Companion Diagnostic Tests Industry Trends
1.3.2 Companion Diagnostic Tests 麻豆原创 Drivers & Opportunity
1.3.3 Companion Diagnostic Tests 麻豆原创 Challenges
1.3.4 Companion Diagnostic Tests 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Companion Diagnostic Tests Players Revenue Ranking (2023)
2.2 Global Companion Diagnostic Tests Revenue by Company (2019-2024)
2.3 Key Companies Companion Diagnostic Tests Manufacturing Base Distribution and Headquarters
2.4 Key Companies Companion Diagnostic Tests Product Offered
2.5 Key Companies Time to Begin Mass Production of Companion Diagnostic Tests
2.6 Companion Diagnostic Tests 麻豆原创 Competitive Analysis
2.6.1 Companion Diagnostic Tests 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Companion Diagnostic Tests Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Companion Diagnostic Tests as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Protein Detection
3.1.2 DNA Detection
3.1.3 Hybridization
3.1.4 Biomarker
3.1.5 Others
3.2 Global Companion Diagnostic Tests Sales Value by Type
3.2.1 Global Companion Diagnostic Tests Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Companion Diagnostic Tests Sales Value, by Type (2019-2030)
3.2.3 Global Companion Diagnostic Tests Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Pharmaceutical and Biotechnology Companies
4.1.2 Medical Device Companies
4.1.3 Research Institutes
4.2 Global Companion Diagnostic Tests Sales Value by Application
4.2.1 Global Companion Diagnostic Tests Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Companion Diagnostic Tests Sales Value, by Application (2019-2030)
4.2.3 Global Companion Diagnostic Tests Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Companion Diagnostic Tests Sales Value by Region
5.1.1 Global Companion Diagnostic Tests Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Companion Diagnostic Tests Sales Value by Region (2019-2024)
5.1.3 Global Companion Diagnostic Tests Sales Value by Region (2025-2030)
5.1.4 Global Companion Diagnostic Tests Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Companion Diagnostic Tests Sales Value, 2019-2030
5.2.2 North America Companion Diagnostic Tests Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Companion Diagnostic Tests Sales Value, 2019-2030
5.3.2 Europe Companion Diagnostic Tests Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Companion Diagnostic Tests Sales Value, 2019-2030
5.4.2 Asia Pacific Companion Diagnostic Tests Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Companion Diagnostic Tests Sales Value, 2019-2030
5.5.2 South America Companion Diagnostic Tests Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Companion Diagnostic Tests Sales Value, 2019-2030
5.6.2 Middle East & Africa Companion Diagnostic Tests Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Companion Diagnostic Tests Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Companion Diagnostic Tests Sales Value
6.3 United States
6.3.1 United States Companion Diagnostic Tests Sales Value, 2019-2030
6.3.2 United States Companion Diagnostic Tests Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Companion Diagnostic Tests Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Companion Diagnostic Tests Sales Value, 2019-2030
6.4.2 Europe Companion Diagnostic Tests Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Companion Diagnostic Tests Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Companion Diagnostic Tests Sales Value, 2019-2030
6.5.2 China Companion Diagnostic Tests Sales Value by Type (%), 2023 VS 2030
6.5.3 China Companion Diagnostic Tests Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Companion Diagnostic Tests Sales Value, 2019-2030
6.6.2 Japan Companion Diagnostic Tests Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Companion Diagnostic Tests Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Companion Diagnostic Tests Sales Value, 2019-2030
6.7.2 South Korea Companion Diagnostic Tests Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Companion Diagnostic Tests Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Companion Diagnostic Tests Sales Value, 2019-2030
6.8.2 Southeast Asia Companion Diagnostic Tests Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Companion Diagnostic Tests Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Companion Diagnostic Tests Sales Value, 2019-2030
6.9.2 India Companion Diagnostic Tests Sales Value by Type (%), 2023 VS 2030
6.9.3 India Companion Diagnostic Tests Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 F. Hoffman LA Roche Ltd.
7.1.1 F. Hoffman LA Roche Ltd. Profile
7.1.2 F. Hoffman LA Roche Ltd. Main Business
7.1.3 F. Hoffman LA Roche Ltd. Companion Diagnostic Tests Products, Services and Solutions
7.1.4 F. Hoffman LA Roche Ltd. Companion Diagnostic Tests Revenue (US$ Million) & (2019-2024)
7.1.5 F. Hoffman LA Roche Ltd. Recent Developments
7.2 QIAGEN, Illumina, Inc.
7.2.1 QIAGEN, Illumina, Inc. Profile
7.2.2 QIAGEN, Illumina, Inc. Main Business
7.2.3 QIAGEN, Illumina, Inc. Companion Diagnostic Tests Products, Services and Solutions
7.2.4 QIAGEN, Illumina, Inc. Companion Diagnostic Tests Revenue (US$ Million) & (2019-2024)
7.2.5 QIAGEN, Illumina, Inc. Recent Developments
7.3 Abbott
7.3.1 Abbott Profile
7.3.2 Abbott Main Business
7.3.3 Abbott Companion Diagnostic Tests Products, Services and Solutions
7.3.4 Abbott Companion Diagnostic Tests Revenue (US$ Million) & (2019-2024)
7.3.5 Agilent Technologies, Inc. Recent Developments
7.4 Agilent Technologies, Inc.
7.4.1 Agilent Technologies, Inc. Profile
7.4.2 Agilent Technologies, Inc. Main Business
7.4.3 Agilent Technologies, Inc. Companion Diagnostic Tests Products, Services and Solutions
7.4.4 Agilent Technologies, Inc. Companion Diagnostic Tests Revenue (US$ Million) & (2019-2024)
7.4.5 Agilent Technologies, Inc. Recent Developments
7.5 Genomic Health, Inc.
7.5.1 Genomic Health, Inc. Profile
7.5.2 Genomic Health, Inc. Main Business
7.5.3 Genomic Health, Inc. Companion Diagnostic Tests Products, Services and Solutions
7.5.4 Genomic Health, Inc. Companion Diagnostic Tests Revenue (US$ Million) & (2019-2024)
7.5.5 Genomic Health, Inc. Recent Developments
7.6 BioMerieux SA, BioGenex
7.6.1 BioMerieux SA, BioGenex Profile
7.6.2 BioMerieux SA, BioGenex Main Business
7.6.3 BioMerieux SA, BioGenex Companion Diagnostic Tests Products, Services and Solutions
7.6.4 BioMerieux SA, BioGenex Companion Diagnostic Tests Revenue (US$ Million) & (2019-2024)
7.6.5 BioMerieux SA, BioGenex Recent Developments
7.7 AGENDIA NV
7.7.1 AGENDIA NV Profile
7.7.2 AGENDIA NV Main Business
7.7.3 AGENDIA NV Companion Diagnostic Tests Products, Services and Solutions
7.7.4 AGENDIA NV Companion Diagnostic Tests Revenue (US$ Million) & (2019-2024)
7.7.5 AGENDIA NV Recent Developments
7.8 Siemens Healthcare GmBH
7.8.1 Siemens Healthcare GmBH Profile
7.8.2 Siemens Healthcare GmBH Main Business
7.8.3 Siemens Healthcare GmBH Companion Diagnostic Tests Products, Services and Solutions
7.8.4 Siemens Healthcare GmBH Companion Diagnostic Tests Revenue (US$ Million) & (2019-2024)
7.8.5 Siemens Healthcare GmBH Recent Developments
7.9 Thermo Fisher Scientific, Inc.
7.9.1 Thermo Fisher Scientific, Inc. Profile
7.9.2 Thermo Fisher Scientific, Inc. Main Business
7.9.3 Thermo Fisher Scientific, Inc. Companion Diagnostic Tests Products, Services and Solutions
7.9.4 Thermo Fisher Scientific, Inc. Companion Diagnostic Tests Revenue (US$ Million) & (2019-2024)
7.9.5 Thermo Fisher Scientific, Inc. Recent Developments
8 Industry Chain Analysis
8.1 Companion Diagnostic Tests Industrial Chain
8.2 Companion Diagnostic Tests Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Companion Diagnostic Tests Sales Model
8.5.2 Sales Channel
8.5.3 Companion Diagnostic Tests Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

F. Hoffman LA Roche Ltd.
QIAGEN, Illumina, Inc.
Abbott
Agilent Technologies, Inc.
Genomic Health, Inc.
BioMerieux SA, BioGenex
AGENDIA NV
Siemens Healthcare GmBH
Thermo Fisher Scientific, Inc.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.